Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice

Despite ongoing vaccination efforts to prevent SARS-CoV-2 infections, treatment tools are still necessary to address the ongoing COVID-19 pandemic. We report here that COVID-HIGIV, a human immunoglobulin product for treatment of COVID-19, provided a significant survival benefit in SARS-CoV-2 infected transgenic mice compared to controls. COVID-HIGIV also has similar pharmacokinetic profiles in healthy and SARS-CoV-2 infected mice over time after intravenous administration, with identical or comparable Tmax, Cmax, AUC(0-infinity) and Cl. AUC(0-last) increased and mean residence time, T-1/2, and Vd reduced in infected animals compared to healthy animals. These data suggest that COVID-HIGIV may be an effective treatment for SARS-CoV-2 infection when given early after exposure.

Automated summary

Despite vaccination efforts, treatment tools are still necessary for COVID-19. COVID-HIGIV showed significant survival benefit in SARS-CoV-2 infected mice and had similar pharmacokinetic profiles in healthy and infected mice. These findings suggest that early administration of COVID-HIGIV may be an effective treatment for SARS-CoV-2 infection.